tiprankstipranks
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
US Market
BMRN
BioMarin Pharmaceutical
RESEARCH TOOLSreports
Want to see BMRN full AI Analyst Report?

BioMarin Pharmaceutical (BMRN) Stock News & Sentiment

2,404 Followers
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio
Premium
Company Announcements
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio
5d ago
8K
BMRN
BMRN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
BMRN Upcoming Earnings Report: What to Expect?
6d ago
BMRN
BioMarin set to acquire Amicus after regulatory clearance
Premium
Company Announcements
BioMarin set to acquire Amicus after regulatory clearance
9d ago
8K
BMRN
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial
Premium
Company Announcements
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial
9d ago
BMRN
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
Premium
Company Announcements
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
2M ago
BMRN
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
Premium
Ratings
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
2M ago
BMRN
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
Premium
Company Announcements
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
2M ago
8K
BMRN
More BMRN News >

BMRN News on the Web

Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (ALLO), Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)
TipRanks News
Neutral
RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
TipRanks News
Bearish
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
Zacks
Neutral
How CNBC Cures is bringing rare disease stories to a national audience
CNBC
Neutral
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
Buy Rating on BioMarin: Strong Early Voxzogo Data, Real‑World Durability, and Underpenetrated Achondroplasia Opportunity Drive Upside
TipRanks News
Neutral
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
BMRN
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BMRN’s Media Buzz Sentiment?
1 articles about BMRN were published this week. In an average week, 1 articles are published.
    What is BMRN’s weekly average amount of articles?
    In an average week, 1 articles about BMRN are published.
      What is BMRN’s News Sentiment?
      50% of articles about BMRN were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week